Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Research-evidence gap analysis of hypofractionated radiotherapy for breast cancer: a bibliometric knowledge graph study.Frontiers in oncology · 2026Pooled it
- Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma.The Cochrane database of systematic reviews · 2025Pooled it
- Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma.The Cochrane database of systematic reviews · 2024Pooled it
- Trial
- In mantle cell lymphoma, whether 18 F-FDG PET/CT or flow cytometry provide superior diagnostic performance compared to biopsy in the determination of bone marrow involvement and enhance prognostic predictive value.Annals of hematology · 2026Review
- Newly Diagnosed Classical Hodgkin Lymphoma: Optimizing Outcomes in a New Therapeutic Era.Hematological oncology · 2025Review
- Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study.Blood advances · 2025Article
- Modified Endothelial Activation and Stress Index: A New Predictor for Survival Outcomes in Classical Hodgkin Lymphoma Treated with Doxorubicin-Bleomycin-Vinblastine-Dacarbazine-Based Therapy.Diagnostics (Basel, Switzerland) · 2025Article
- Different Role of PET-CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab-Based Chemotherapy and Chemo-Free Immunotherapy.Hematological oncology · 2025Article
- Prognostic Factors and Outcomes of Early-Stage Hodgkin's Lymphoma: Multi-Institutional Data From South India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024Article
- Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD.Frontiers in oncology · 2024Article
- Management of limited-stage Hodgkin lymphoma.Hematology. American Society of Hematology. Education Program · 2023Article
- Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma.International journal of molecular sciences · 2023Review
- FocalThoracic cancer · 2023Article
- Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical).Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Review
- Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
- Positron Emission Tomography Molecular Imaging for Phenotyping and Management of Lymphoma.Phenomics (Cham, Switzerland) · 2022Review
- Controversies in the management of early-stage Hodgkin lymphoma.Hematology. American Society of Hematology. Education Program · 2021Article
- Current Role of Functional Imaging in the Management of Lymphoma.Current oncology reports · 2021Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
15 authors at 10 institutions in 1 country.
Funding
Abstract
purposeAccurate stratification of patients is an important goal in Hodgkin lymphoma (HL), but the role of pretreatment clinical risk stratification in the context of positron emission tomography (PET) -adapted treatment is unclear. We performed a subsidiary analysis of the RAPID trial to assess the prognostic value of pretreatment risk factors and PET score in determining outcomes. PATIENTS AND
methodsPatients with stage IA to IIA HL and no mediastinal bulk underwent PET assessment after three cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine; 143 PET-positive patients (PET score, 3 to 5) received a fourth doxorubicin, bleomycin, vinblastine, and dacarbazine cycle and involved-field radiotherapy, and 419 patients in complete metabolic remission were randomly assigned to receive involved-field radiotherapy (n = 208) or no additional treatment (n = 211). Cox regression was used to investigate the association between PET score and pretreatment risk factors with HL-specific event-free survival (EFS).
resultsHigh PET score was associated with inferior EFS, before (
conclusionIn RAPID, a positive PET scan did not carry uniform prognostic weight; only a PET score of 5 was associated with inferior outcomes. This suggests that in future trials involving patients without B symptoms or mediastinal bulk, a score of 5 rather than a positive PET result should be used to guide treatment escalation in early-stage HL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.